{"organizations": [], "uuid": "82f63a9bdb951477e59a08a91e5747801b42ec39", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-iqvia-responds-to-fda-statement-re/brief-iqvia-responds-to-fda-statement-regarding-conversion-measurement-issue-idUSFWN1SN0UJ", "country": "US", "domain_rank": 408, "title": "BRIEF-IQVIA Responds To FDA Statement Regarding Conversion Measurement Issue", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-17T03:08:00.000+03:00", "replies_count": 0, "uuid": "82f63a9bdb951477e59a08a91e5747801b42ec39"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-iqvia-responds-to-fda-statement-re/brief-iqvia-responds-to-fda-statement-regarding-conversion-measurement-issue-idUSFWN1SN0UJ", "ord_in_thread": 0, "title": "BRIEF-IQVIA Responds To FDA Statement Regarding Conversion Measurement Issue", "locations": [], "entities": {"persons": [{"name": "iqvia", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "iqvia holdings inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - IQVIA Holdings Inc:\n* IQVIA RESPONSE TO FDA STATEMENT * IQVIA HOLDINGS - RECENTLY MADE CORRECTION TO KILOGRAM CONVERSION MEASUREMENT IN UNITED STATES IQVIA NATIONAL SALES PERSPECTIVE MARKET RESEARCH SERVICE\n* IQVIA HOLDINGS INC - CORRECTION AFFECTS REPORTED MEASUREMENTS FOR TRANSDERMAL PATCHES IN OPIOID MARKET\n* IQVIA HOLDINGS INC - IQVIA’S INTERNAL PROCESSES HAD ALREADY IDENTIFIED MEASUREMENT CONVERSION ISSUE PRIOR TO FDA’S NOTIFICATION\n* IQVIA HOLDINGS INC - NOTIFIED CO’S CLIENTS ABOUT THE MEASUREMENT CONVERSION ISSUE IN APRIL OF THIS YEAR\n* IQVIA - MEASUREMENT CONVERSION ISSUE DOES NOT IMPACT WIDELY USED U.S. & GLOBAL DOLLAR & UNIT INFORMATION IN NATIONAL SALES PERSPECTIVE\n* IQVIA HOLDINGS INC - ONGOING STEPS HAVE BEEN UNDERTAKEN TO CORRECT THE MEASUREMENT CONVERSION ISSUE IN THIS OFFERING\n* IQVIA HOLDINGS INC - WILL CONTINUE WORKING WITH FDA TO RESOLVE THE CONCERNS\n* IQVIA - MEASUREMENT CONVERSION ISSUE DOES NOT IMPACT INFORMATION IN ANY OTHER IQVIA MARKET RESEARCH SERVICES, METHODOLOGIES OR OFFERINGS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T03:08:00.000+03:00", "crawled": "2018-05-17T14:28:03.043+03:00", "highlightTitle": ""}